Truist Financial Maintains Edgewise Therapeutics(EWTX.US) With Buy Rating, Maintains Target Price $33
Edgewise Therapeutics (EWTX) Gets a Buy From Truist Financial
Truist Financial Maintains Edgewise Therapeutics(EWTX.US) With Buy Rating, Maintains Target Price $33
Wedbush Maintains Edgewise Therapeutics(EWTX.US) With Buy Rating, Raises Target Price to $44
Edgewise Therapeutics Analyst Ratings
Leerink Partners Maintains Edgewise Therapeutics(EWTX.US) With Buy Rating, Announces Target Price $42
Buy Rating Affirmed on Edgewise Therapeutics' EDG-7500 for HCM Treatment Due to Promising Efficacy and Safety Profile
Edgewise Therapeutics Is Maintained at Buy by Truist Securities
Wedbush Adjusts Edgewise Therapeutics Price Target to $44 From $31, Maintains Outperform Rating
Truist Financial Maintains Edgewise Therapeutics(EWTX.US) With Buy Rating, Announces Target Price $33
Truist Financial Maintains Edgewise Therapeutics(EWTX.US) With Buy Rating
Truist Financial Reaffirms Their Buy Rating on Edgewise Therapeutics (EWTX)
Piper Sandler Maintains Edgewise Therapeutics(EWTX.US) With Buy Rating, Maintains Target Price $48
RBC Capital Maintains Edgewise Therapeutics(EWTX.US) With Buy Rating, Maintains Target Price $32
Edgewise Therapeutics Is Maintained at Outperform by RBC Capital
Optimistic Buy Rating for Edgewise Therapeutics Amid Promising EDG-7500 Developments
Edgewise Therapeutics Price Target Maintained With a $31.00/Share by Wedbush
Edgewise Therapeutics Analyst Ratings
Wedbush Maintains Edgewise Therapeutics(EWTX.US) With Buy Rating, Maintains Target Price $31
Wedbush Sticks to Their Buy Rating for Edgewise Therapeutics (EWTX)